– ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- – Kiniks ...

DANBURY, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq: FCEL) -- announced the upcoming release of its first quarter 2026 results prior to the Stock Market Open on Monday, March 9, 2026. FuelCell Energy management will subsequently host a conference call with investors beginning at 10:00 a.m. Eastern Time the same day to discuss the results and provide a business update. Participants can access the live call via webcast on the Company website or by telephone as follows: The live web ...

Core Viewpoint - PTL Limited has announced the approval of a 1-for-80 share consolidation of its Class A and Class B ordinary shares to regain compliance with Nasdaq listing requirements [1][2]. Share Consolidation Details - The share consolidation will take effect on February 27, 2026, with Class A Ordinary Shares trading under the same symbol "PTLE" but with a new CUSIP number G7377S127 [2]. - Currently, there are 491,237,500 Class A Ordinary Shares and 11,250,000 Class B Ordinary Shares outstanding. Post-consolidation, there will be 6,140,469 Class A Ordinary Shares and 140,625 Class B Ordinary Shares outstanding [3]. - The consolidation will not result in fractional shares; any fractions will be rounded up to the next whole number [3]. Company Overview - PTL Limited is headquartered in Hong Kong and operates as a bunkering facilitator, providing marine fuel logistics services primarily for container ships, bulk carriers, general cargo vessels, and chemical tankers [4]. - The company targets the Asia Pacific market and leverages its established network within the marine fuel logistics industry to offer a one-stop solution for vessel refueling [4].

Core Viewpoint - Allied Properties Real Estate Investment Trust has received approval for a normal course issuer bid to repurchase up to 18,215,302 units, representing approximately 10% of its public float, primarily to fulfill employee commitments and potentially for cancellation [1][2]. Group 1: Normal Course Issuer Bid (NCIB) Details - The NCIB will commence on February 26, 2026, and will expire on February 25, 2027, or earlier if purchases are completed [2]. - Purchases will be made on the open market at prevailing market prices, with a daily limit of 213,464 units, which is 25% of the average daily trading volume over the past six months [2]. - The previous NCIB, which started on February 26, 2025, allowed for the purchase of up to 12,615,599 units, with 1,062 units repurchased at a weighted average price of $16.86 [3]. Group 2: Employee Programs and Repurchase Plans - The primary purpose of the NCIB is to fulfill commitments under Allied's restricted unit plan and other employee programs [1]. - Allied may enter into pre-defined plans with its broker to repurchase units during internal trading blackout periods, adhering to Canadian securities laws [4]. Group 3: Company Overview - Allied is a leading owner-operator of distinctive urban workspace in major Canadian cities, focusing on sustainable and wellness-oriented environments for knowledge-based organizations [6].

Core Insights - Quantum Transportation has successfully implemented its transformer-based neural decoder on the AWS cloud, marking a significant milestone for real-world quantum applications in the transportation sector [1][2] - The cloud deployment provides scalable infrastructure for processing complex quantum data efficiently, enhancing the potential for collaboration with quantum hardware design partners [2][3] - The technology aims to address error correction challenges in noisy quantum devices, with long-term applications in railway anomaly detection, predictive maintenance, and autonomous operations [3] Company Developments - Rail Vision Ltd. has acquired a 51% stake in Quantum Transportation, enhancing its focus on integrating quantum-AI innovations into the transportation sector [4] - Quantum Transportation is developing a Quantum Error Correction Simulator powered by a patented Transformer-based Universal Decoder, which aims to outperform classical decoders in accuracy and speed [5] - The patented Deep Quantum Error Correction Transformer introduces a novel machine-learning decoder that optimizes error correction across various quantum codes [5] Industry Impact - Rail Vision's technology is designed to transform railway safety and efficiency, potentially advancing the concept of autonomous trains into practical reality [6] - The integration of quantum error correction with AI-driven vision systems is expected to enhance safety and operational efficiency in railway operations [4][6]

Core Insights - Novartis announced new real-world studies on Pluvicto™ for metastatic prostate cancer, utilizing data from the PRECISION platform, to be presented at the ASCO Genitourinary Cancers Symposium [1] Group 1: Efficacy of Pluvicto - Pluvicto demonstrated a median progression-free survival (PFS) of 13.5 months in taxane-naïve mCRPC patients who had received at least one ARPI, with longer PFS observed in those treated after one ARPI (15.8 months) compared to multiple ARPIs (12.7 months) [2][3] - The findings align with the PSMAfore trial, which showed that Pluvicto more than doubled median rPFS compared to a change in ARPI (11.6 months vs. 5.6 months) [3] Group 2: Subsequent Therapies - A study indicated that mCRPC patients achieved meaningful clinical responses with systemic therapies after discontinuing Pluvicto, with median PFS of 8.6 months for all subsequent therapies [5][6] - Patients receiving ARPI after Pluvicto had a median PFS of 10.7 months, while those receiving taxane had a median PFS of 7.2 months [6] Group 3: Treatment Patterns and Guidelines - Real-world evidence showed significant gaps in guideline adherence for metastatic hormone-sensitive prostate cancer (mHSPC), with 39.2% of men receiving ADT monotherapy instead of the recommended combination therapy [8] - The data highlights an opportunity for improved patient care through adherence to clinical guidelines [8] Group 4: PRECISION Data Platform - The PRECISION platform harmonizes data from over 56,500 patients with metastatic prostate cancer to generate real-world evidence studies that inform clinical decisions [9]

Core Viewpoint - Gilat Satellite Networks Ltd. has received $39 million in orders for its Sidewinder electronically steered antenna (ESA) terminals, indicating a significant rise in global demand for advanced in-flight connectivity solutions [1][2]. Group 1: Company Overview - Gilat Satellite Networks Ltd. is a leading global provider of satellite-based broadband communications with over 35 years of experience [4]. - The company develops and delivers technology solutions for satellite, ground, and new space connectivity, focusing on critical connectivity across commercial and defense applications [4]. Group 2: Product and Market Demand - The new orders for Sidewinder ESA terminals reflect an accelerating global shift towards ESA solutions as airlines and service providers aim to meet the growing demand for high-quality in-flight broadband [2][3]. - The Sidewinder ESA terminal is designed for both linefit and retrofit installations, providing a high-quality connectivity experience across various aircraft types and flight paths [2][3]. Group 3: Strategic Positioning - Demand for high-performance ESA terminals is increasing as airlines seek seamless broadband connectivity across different geographies and satellite constellations [3]. - The Sidewinder ESA terminal offers efficiency, flexibility, and reliability, reinforcing Gilat's leadership in the expanding market for advanced in-flight connectivity across LEO, MEO, and GEO orbits [3].

Core Viewpoint - Enphase Energy, Inc. is facing a class action lawsuit for allegedly making false statements and failing to disclose critical information regarding its financial and operational prospects during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Tripathi v. Enphase Energy, Inc., and it includes purchasers or acquirers of Enphase Energy securities from April 22, 2025, to October 28, 2025 [1]. - Investors have until April 20, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Enphase Energy overstated its ability to manage channel inventory and mitigate the effects of the termination of the Residential Clean Energy Credit [3]. Group 2: Financial Impact - On October 28, 2025, Enphase Energy reported third-quarter financial results, indicating that elevated channel inventory would lead to lower battery storage shipments in the fourth quarter of 2025 [4]. - The expiration of the 25D Credit is expected to negatively impact revenues for the first quarter of 2026 [4]. - Following the announcement, Enphase Energy's stock price fell by more than 15% [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Enphase Energy securities during the class period to seek appointment as lead plaintiff [5]. - A lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years [6].

Core Viewpoint - Treace Medical Concepts, Inc. is set to showcase new product innovations and present interim data from its clinical studies at the ACFAS Annual Scientific Conference, emphasizing advancements in surgical treatments for bunions and related midfoot deformities [1][2]. Product Innovations - The company will highlight next-generation Lapiplasty instrumentation and fixation technology platforms, including SpeedTMT, Lapiplasty Lightning System, Nanoplasty, Percuplasty, SpeedMTP, and IntelliGuide PSI, aimed at enhancing surgical outcomes and market penetration [2][4]. - SpeedTMT is a new Lapiplasty fixation option utilizing hybrid technology, expected to be fully commercialized in the second half of 2026 [4]. - The Lapiplasty Lightning System is designed for greater accuracy and control in 3D correction, with full commercialization anticipated in late 2026 [4]. - Nanoplasty and Percuplasty are minimally invasive systems designed for efficient access to 3D osteotomies, with unique features to enhance surgical precision and recovery [4]. Clinical Study Presentations - The ALIGN3D clinical study will present interim data showing early return to weight bearing at an average of 8.4 days and low recurrence rates of 8.4% at 48 months [5][6]. - The MTA3D clinical study will present interim analysis demonstrating significant improvements in radiographic measures and patient-reported outcomes through 24 months [12]. - A retrospective study on the SpeedMTP system will show early return to weight bearing at an average of 3.7 days, with full radiographic union achieved in all patients at 6 months [8]. Company Overview - Treace Medical Concepts aims to advance the standard of care for bunion and midfoot deformities, addressing a significant market with approximately 67 million affected Americans, of which 1.1 million are surgical candidates annually [14]. - The company has developed the Lapiplasty 3D Bunion Correction System, which corrects bunion deformities in all three planes and secures the unstable joint, facilitating patient recovery [14].

Core Viewpoint - First Watch Restaurant Group, Inc. announces the retirement of Chief Financial Officer Mel Hope, who will assist in the transition to his successor, ensuring continuity in financial leadership [1][2][3] Company Leadership Transition - Mel Hope has been with First Watch since 2018 and has played a crucial role in guiding the company through its IPO and various growth phases [2] - The company is actively seeking both internal and external candidates for the CFO position, with Hope expected to remain until a successor is appointed [1][2] Company Overview - First Watch is recognized as a leading Daytime Dining concept, specializing in made-to-order breakfast, brunch, and lunch using fresh ingredients [3] - The company operates over 630 restaurants across 32 states and has received multiple awards, including 1 Best Breakfast by Newsweek's Readers' Choice Awards 2025 [3] - First Watch has a commitment to community impact, having raised approximately $2.0 million through donations linked to children's meals served [3]